| 13.86 -0.27 (-1.91%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.24 | 1-year : | 20.14 |
| Resists | First : | 14.76 | Second : | 17.24 |
| Pivot price | 14.02 |
|||
| Supports | First : | 13.34 | Second : | 12.46 |
| MAs | MA(5) : | 14.05 |
MA(20) : | 13.79  |
| MA(100) : | 14.24 |
MA(250) : | 18.52 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 69 |
D(3) : | 69.1 |
| RSI | RSI(14): 52.9 |
|||
| 52-week | High : | 34.13 | Low : | 10.86 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NVCR ] has closed above bottom band by 40.3%. Bollinger Bands are 41.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.46 - 14.54 | 14.54 - 14.63 |
| Low: | 13.58 - 13.67 | 13.67 - 13.77 |
| Close: | 13.69 - 13.85 | 13.85 - 14.01 |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Sun, 19 Oct 2025
How Novocure Limited (NVCR) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Sun, 19 Oct 2025
NovoCure (NVCR): Evaluating the Stock's Valuation After Recent 9% Move - simplywall.st
Sat, 18 Oct 2025
NovoCure (NVCR): Evaluating Valuation as Share Price Stabilizes After Recent Volatility - Yahoo Finance
Fri, 17 Oct 2025
New TTFields Data Presentations Might Change The Case For Investing In NovoCure (NVCR) - Sahm
Fri, 17 Oct 2025
New TTFields Data Presentations Might Change The Case For Investing In NovoCure (NVCR) - simplywall.st
Fri, 17 Oct 2025
NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 112 (M) |
| Shares Float | 94 (M) |
| Held by Insiders | 9.8 (%) |
| Held by Institutions | 85.5 (%) |
| Shares Short | 5,750 (K) |
| Shares Short P.Month | 5,970 (K) |
| EPS | -1.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.13 |
| Profit Margin | -27.2 % |
| Operating Margin | -24.9 % |
| Return on Assets (ttm) | -8.7 % |
| Return on Equity (ttm) | -48.1 % |
| Qtrly Rev. Growth | 5.5 % |
| Gross Profit (p.s.) | 4.31 |
| Sales Per Share | 5.63 |
| EBITDA (p.s.) | -1.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -8.89 |
| PEG Ratio | 0 |
| Price to Book value | 4.42 |
| Price to Sales | 2.45 |
| Price to Cash Flow | -34.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|